ACE and hypertensive disorder: Zhou et al reported that the most common comorbidities accompanying COVID-19 were hypertension (30%), diabetes (19%), and coronary heart disease (8%).[81] Additionally, there is no evidence suggesting that the use of ACE inhibitors or ARBs is harmful or beneficial during the COVID-19 pandemic.